Content discovery platform

Machine Discovery Collaborates with First Light Fusion to Accelerate Advanced Innovations in Clean Energy

Retrieved on: 
Monday, January 30, 2023
Engineering, Content discovery platform, Acceleration, Laser, First Light, Algorithm, Physics-informed neural networks, 3D printing

SANTA CLARA, Calif., Jan. 30, 2023 /PRNewswire/ -- Machine Discovery's AI-powered Discovery Platform is delivering acceleration for compute-intensive optimization and prediction tasks and is adopted by First Light Fusion. As a result of a multi-year close collaboration between the two companies, the Discovery Platform is now proven to accelerate the development of the key technologies required to deliver fusion clean energy at record speed.   

Key Points: 
  • First Light Fusion is a UK-based leading fusion pioneer seeking to deliver fusion energy using its unique 'projectile' approach – a branch of inertial confinement fusion that uses high-velocity projectiles rather than lasers.
  • In deploying the Discovery Platform, First Light Fusion achieved the ability to explore the design space in record time to find an optimum fusion solution.
  • Machine Discovery's latest collaboration with First Light Fusion resulted in a solution that significantly speeds up optimization tasks with high-quality of results.
  • This work is well aligned with our strategy of contributing towards the development of low-cost clean energy in enabling First Light Fusion to develop complex fusion reactors to a significantly reduced schedule."

Zoovu Appoints James Novak as CEO

Retrieved on: 
Tuesday, January 10, 2023
Finance, Banking, Professional Services, Technology, Artificial Intelligence, Attention, B2B, NYSE, Rockwell Automation, AI, B2C, Growth, Paralysis, Software, Friction, Microsoft, Software as a service, Blackberry, Whirlpool, Content discovery platform, Sales, Video game, Online shopping

Zoovu, an AI-powered Discovery Experience Platform for B2B and B2C e-commerce, today announced the appointment of James Novak as chief executive officer.

Key Points: 
  • Zoovu, an AI-powered Discovery Experience Platform for B2B and B2C e-commerce, today announced the appointment of James Novak as chief executive officer.
  • Novak brings more than two decades of enterprise SaaS experience scaling companies globally and building AI-driven, multi-product platforms.
  • Before joining Zoovu, Novak served as CEO of Fiix, a cloud-based, AI-enabled asset management and maintenance software platform that empowers industrial companies to modernize their operations.
  • “I am thrilled to join Zoovu as CEO at a pivotal time for the company as we embark on this next chapter of long-term growth and market expansion,” said Novak.

hC Bioscience and 4SR Biosciences Join Forces to Expand Platform Development of tRNA-Based Therapies

Retrieved on: 
Tuesday, January 17, 2023
Tao, Molecular biology, RNA transfection, Associate, SAB, University, Biology, Therapy, Biochemistry, Cancer, IP, Acquisition, Chicago (franchise), United States Air Force Scientific Advisory Board, Content discovery platform, Pharmaceutical industry, Telescopic sight

Cambridge, Massachusetts--(Newsfile Corp. - January 17, 2023) - hC Bioscience, a pioneer in the development of tRNA-based therapeutics, has acquired 4SR Biosciences to combine technologies, IP, and know-how to advance the development of first-in-class tRNA-based therapeutics.

Key Points: 
  • Cambridge, Massachusetts--(Newsfile Corp. - January 17, 2023) - hC Bioscience, a pioneer in the development of tRNA-based therapeutics, has acquired 4SR Biosciences to combine technologies, IP, and know-how to advance the development of first-in-class tRNA-based therapeutics.
  • As part of the acquisition, Tao Pan, Ph.D., Professor of Biochemistry and Molecular Biology and a pioneer in tRNA technology and biology, will join hC Bioscience as a scientific advisor and member of its Scientific Advisory Board, Christopher Katanski, Ph.D., will join hC Bioscience as Director of Discovery Platform and Philip McGilvray, Ph.D., will join as Associate Director of Discovery Platform.
  • hC Bioscience and 4SR Biosciences consolidate complementary technologies, IP and know-how related to the design and development of tRNA-based therapies.
  • Tao Pan, Ph.D., Professor of Biochemistry and Molecular Biology at the University of Chicago to join hC Bioscience as a scientific advisor and member of the SAB; Christopher Katanski, Ph.D. to join hC Bioscience as Director of Discovery Platform and Philip McGilvray, Ph.D. to join as Associate Director of Discovery Platform.

Candel Therapeutics R&D Day Presentations Spotlight its Advanced Pipeline and Capabilities to Develop Novel Viral Immunotherapies for Patients with Cancer

Retrieved on: 
Tuesday, December 6, 2022
Prostate cancer, HGG, Clinical trial, Research, Progression-free survival, Partnership, SOC, DRS, Cancer, HSV, CADL, Large-cell lung carcinoma, Immunogenic cell death, Doctor of Philosophy, MD, Toxicity, Content discovery platform, Therapy, Standard of care, Biology, University, Development, Patient, University of Pennsylvania, Pharmaceutical industry, Vaccine, Online shopping, Candel, Fellow of the Academy of Medical Sciences

“The totality of clinical data demonstrates that CAN-2409 and CAN-3110 are active investigational viral immunotherapies with robust biomarker evidence of local and systemic immune responses.

Key Points: 
  • “The totality of clinical data demonstrates that CAN-2409 and CAN-3110 are active investigational viral immunotherapies with robust biomarker evidence of local and systemic immune responses.
  • Candel is a clinical stage biopharmaceutical company focused on helping patients fight cancer with viral immunotherapies.
  • Candel has established two viral immunotherapy platforms based on novel, genetically modified adenovirus and HSV constructs, respectively.
  • Candel’s enLIGHTEN™ Discovery Platform is the first systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors.

Candel Therapeutics Announces Oral Presentation of Updated Data from its Phase 1 Clinical Trial of CAN-3110 in 41 Patients with Recurrent High-Grade Glioma at the Society for Neuro-Oncology 27th Annual Meeting

Retrieved on: 
Friday, November 18, 2022
Doctor of Philosophy, Immunogenic cell death, Glioblastoma, Therapy, Brain, Patient, Virulence, Data, Society, Neoplasm, Tumor microenvironment, Injection, SNO, Disease, MD, HSV, CADL, Nestin, Cancer, Form, Pakistan Society of Neuro-Oncology, Content discovery platform, Clinical trial, Survival, Biology, Pharmaceutical industry, Vaccine, Fellow of the Academy of Medical Sciences, Candel

An overview of this data will be presented in-person at the Society for Neuro-Oncology (SNO) 27th Annual Meeting today starting at 5:30 pm ET in Tampa, Florida.

Key Points: 
  • An overview of this data will be presented in-person at the Society for Neuro-Oncology (SNO) 27th Annual Meeting today starting at 5:30 pm ET in Tampa, Florida.
  • Data will be reported from 41 patients who were administered CAN-3110, with 40 patients having received a single injection and one patient having received two injections.
  • Diversity of the T cell receptor repertoire after CAN-3110 administration was reported to be associated with overall survival.
  • The effects of multiple doses of CAN-3110 in recurrent glioblastoma are currently being evaluated in an ongoing phase 1 clinical trial.

Candel Therapeutics Announces Late-Breaking Oral Presentation at SITC Annual Meeting with Data on CAN-2409 in Combination with Nivolumab in a Phase 1 Mechanistic Clinical Trial in Patients with High-Grade Glioma

Retrieved on: 
Friday, November 11, 2022
GTR, Form, Cytokine, Nivolumab, SITC, Content discovery platform, Company, Gamma ray, Biology, Prostate cancer, MD, Combination therapy, Private Securities Litigation Reform Act, Therapy, Cancer, HSV, Immunotherapy, GLOBE, Doctor of Philosophy, Patient, STR, SEC, CXCL11, Chemokine, CADL, Neoplasm, Tumor microenvironment, MOS, MGMT, Pancreatic cancer, Large-cell lung carcinoma, Immunogenic cell death, Nasdaq, Pharmaceutical industry, Vaccine, Fellow of the Academy of Medical Sciences, Candel

Data were presented at the 37th Annual Meeting of Society for Immunotherapy of Cancer (SITC) today in Boston.

Key Points: 
  • Data were presented at the 37th Annual Meeting of Society for Immunotherapy of Cancer (SITC) today in Boston.
  • Proteomic analysis by OLINK revealed an increase in pro-inflammatory cytokines, including interferon-gamma, the chemokines CXCL9/10 and CXCL11, MCP-1, MCP-3, and granzyme A.
  • Systemic immune activation was observed after the single administration of CAN-2409, prior to initiation of nivolumab (week 3 post treatment).
  • The data support the potential therapeutic synergies between CAN-2409 in combination with immune checkpoint inhibitors across various solid tumors.

Candel Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights

Retrieved on: 
Thursday, November 10, 2022
GLOBE, Content discovery platform, BMO Capital Markets, Credit Suisse, Nivolumab, Leadership, Doctor of Philosophy, Silicon Valley Bank, HGG, Partnership, European Commission, Development, Silicon, Glioma, Board, Large-cell lung carcinoma, Therapy, R, OPKO Health, PD-L1, View, Board of directors, CADL, EMA, Royal commission, Company, Cancer, Standard of care, Clinical trial, Research, European Medicines Agency, Quarter, Conference, University, Patient, Administration, MS, Dana–Farber Cancer Institute, Income, Pharmaceutical industry, Management, Medical device, Immunotherapy, Candel, Fellow of the Academy of Medical Sciences, MD

Virtual R&D Day on December 6, 2022, with Candel leadership and renowned oncology experts

Key Points: 
  • Virtual R&D Day on December 6, 2022, with Candel leadership and renowned oncology experts
    NEEDHAM, Mass., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on helping patients fight cancer with viral immunotherapies, today reported financial results for the third quarter ended September 30, 2022 and provided a corporate update.
  • Candel made important progress across multiple facets of the organization this quarter, said Paul Peter Tak, MD, PhD, FMedSci, President and Chief Executive Officer of Candel.
  • General and Administrative Expenses: General and administrative expenses were $3.5 million for the third quarter of 2022 compared to $2.8 million for the third quarter of 2021.
  • General and administrative expenses includes non-cash stock compensation expense of $400,000 and $390,000 for the third quarter of 2022 and 2021, respectively.

Candel Therapeutics Announces Upcoming Clinical Data Presentations at SITC and SNO

Retrieved on: 
Monday, November 7, 2022
Company, Virus, Private Securities Litigation Reform Act, Content discovery platform, Biology, GLOBE, HSV, SNO, Therapy, Nasdaq, Immunogenic cell death, Immunotherapy, CADL, SEC, Society, SITC, Patient, Cancer, Vaccine, Candel

NEEDHAM, Mass., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Nasdaq: CADL), a clinical stage biopharmaceutical company developing novel viral immunotherapies, today announced new clinical data will be presented in the upcoming 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) in Boston, MA and the 27th Annual Meeting of the Society for Neuro-Oncology (SNO) in Tampa Bay, FL.

Key Points: 
  • NEEDHAM, Mass., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Nasdaq: CADL), a clinical stage biopharmaceutical company developing novel viral immunotherapies, today announced new clinical data will be presented in the upcoming 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) in Boston, MA and the 27th Annual Meeting of the Society for Neuro-Oncology (SNO) in Tampa Bay, FL.
  • CAN-2409 is the lead product candidate from the adenovirus platform and CAN-3110 is the lead product candidate from the HSV platform.
  • TheenLIGHTEN Discovery Platform is the first systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors.
  • The Company cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made.

Candel Therapeutics Upcoming Investor Conference Participation for November

Retrieved on: 
Tuesday, November 1, 2022
Content discovery platform, MD, Immunogenic cell death, Doctor of Philosophy, SEC, Cancer, GLOBE, Virus, Nasdaq, HSV, Private Securities Litigation Reform Act, Company, Therapy, Patient, Biology, CADL, Online shopping, Vaccine, Fellow of the Academy of Medical Sciences, Candel

NEEDHAM, Mass., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Nasdaq: CADL), a clinical stage biopharmaceutical company developing novel viral immunotherapies, today announced that Paul Peter Tak, MD, PhD, FMedSci, President and Chief Executive Officer, will participate in the following investor conferences in November:

Key Points: 
  • NEEDHAM, Mass., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Nasdaq: CADL), a clinical stage biopharmaceutical company developing novel viral immunotherapies, today announced that Paul Peter Tak, MD, PhD, FMedSci, President and Chief Executive Officer, will participate in the following investor conferences in November:
    To access the webcast recordings following the event, please visit the Candel Therapeutics website at https://ir.candeltx.com/news-and-events/events-and-presentations.
  • CAN-2409 is the lead product candidate from the adenovirus platform and CAN-3110 is the lead product candidate from the HSV platform.
  • TheenLIGHTEN Discovery Platform is the first systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors.
  • The Company cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made.

Candel Therapeutics Partners with the University of Pennsylvania’s Center for Cellular Immunotherapies to Study Combinations of Novel Viral Immunotherapy and CAR-T Cell Therapy in Solid Tumor Models

Retrieved on: 
Wednesday, October 26, 2022
SEC, Company, University, Virus, Penn, Science Publishing Group, MD, Doctor of Philosophy, Private Securities Litigation Reform Act, Nasdaq, Cancer, Center, Intellectual property, Tumor microenvironment, Patient, Pathology, Medical laboratory, HSV, Immunogenic cell death, GLOBE, Enlightenment, Therapy, Transgene, Perelman School of Medicine at the University of Pennsylvania, Biology, Content discovery platform, Partnership, CADL, Vaccine, Fellow of the Academy of Medical Sciences, Candel, Immunotherapy

Herpes simplex virus (HSV) vectors containing selected transgenes based on Candel's enLIGHTEN Discovery Platform will be evaluated in combination with investigational CAR-T cell therapies in tumor models.

Key Points: 
  • Herpes simplex virus (HSV) vectors containing selected transgenes based on Candel's enLIGHTEN Discovery Platform will be evaluated in combination with investigational CAR-T cell therapies in tumor models.
  • Under the terms of the agreement, the parties will collaborate to use novel engineered viruses that break down barriers to CAR-T therapies and to evaluate the effects of these combinations in tumor models.
  • Candel is a clinical stage biopharmaceutical company focused on helping patients fight cancer with viral immunotherapies.
  • Candel has established two viral immunotherapy platforms based on novel, genetically modified adenovirus and HSV constructs, respectively.